RxDoctor Payments Data

Hannah Cher Samonte, MD

Family Medicine · Kokomo, INNPI 1902192198

Payments from drug & device makers

$10,905in general payments, 2019–2025

Across 696 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Bayer$859
  • Pfizer$845
  • Lilly USA, LLC$684
  • AstraZeneca$668
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$10,879100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,905 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$56,974
Medicare patients
145
Services billed
5,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$123,337
JardianceEmpagliflozin91$122,000
MounjaroTirzepatide82$105,259
FarxigaDapagliflozin Propanediol56$48,288
LinzessLinaclotide24$29,864
MyrbetriqMirabegron16$20,208
EliquisApixaban21$18,648
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$17,912
RybelsusSemaglutide13$15,770
TradjentaLinagliptin20$14,900
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$12,503
ShingrixVaricella-Zoster Ge/As01b/Pf42$9,261
VascepaIcosapent Ethyl16$5,521
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$5,310
Atorvastatin Calcium427$4,778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,338$139,107122 claims
Boehringer IngelheimJardiance, Tradjenta$444$136,900111 claims
Lilly USA, LLCMounjaro$684$105,25982 claims
AstraZenecaFarxiga, Symbicort$668$51,90469 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix$319$39,67681 claims
AbbVieLinzess$1,275$29,86424 claims
Astellas Pharma US IncMyrbetriq$14$20,20816 claims
PfizerEliquis$845$18,64821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →